{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062019","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.449602+00:00","generated_at":"2026-06-08T07:18:01.259522+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta reports Q3 net loss $25.6M; cash $278.4M; extends runway into 2026","bullets":["Net loss of $25.6M ($0.52 per share) for Q3 2023; R&D expenses $22.2M, G&A $7.1M.","Cash and investments $278.4M as of Sep 30, 2023; cost containment extends cash runway into 2026.","FDA cleared IND for NKX019 in lupus nephritis; first patient dosing expected H1 2024.","Workforce reduced ~10%; operations centralization and manufacturing optimization underway.","Clinical data updates in 2024: NKX101 AML, NKX019 NHL compressed dosing, LN."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062019","json":"https://secwatch.observer/filing/0000950170-23-062019.json","markdown":"https://secwatch.observer/filing/0000950170-23-062019.md","text":"https://secwatch.observer/filing/0000950170-23-062019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/0000950170-23-062019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/nktx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:18:01.259522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d39c2f26295015b93643e8870d173e201f809bc","claim":"Nkarta, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/0000950170-23-062019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}